Compounds > id-6105
Page last updated: 2024-10-15

id-6105

Description

11-hydroxyaclacinomycin X: isolated from Streptomyces galilaeus; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID156613908
MeSH IDM0488313

Synonyms (10)

Synonym
11-hydroxyaclacinomycin x
unii-q8fc7a9s5c
hyrubicin
id6105
methyl (1r,2r,4s)-4-((4-o-(4-o-((2r,6s)-3-amino-5,6-dihydro-6-methyl-5-oxo-2h-pyran-2-yl)-2,6-dideoxy-.alpha.-l-lyxo-hexopyranosyl)-2,3,6-trideoxy-3-(dimethylamino)-.alpha.-l-lyxo-hexopyranosyl)oxy)-2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7,12-tetrahydroxy-6,1
methyl (1r,2r,4s)-4-((2r,4s,5s,6s)-5-((2s,4s,5s,6s)-5-(((2r,6s)-3-amino-6-methyl-5-oxo-2h-pyran-2-yl)oxy)-4-hydroxy-6-methyl-tetrahydropyran-2-yl)oxy-4-(dimethylamino)-6-methyl-tetrahydropyran-2-yl)oxy-2-ethyl-2,5,7,12-tetrahydroxy-6,11-dioxo-3,4-dihydro-
id-6105
Q8FC7A9S5C ,
176665-19-3
1-naphthacenecarboxylic acid, 4-((4-o-(4-o-((2r,6s)-3-amino-5,6-dihydro-6-methyl-5-oxo-2h-pyran-2-yl)-2,6-dideoxy-.alpha.-l-lyxo-hexopyranosyl)-2,3,6-trideoxy-3-(dimethylamino)-.alpha.-l-lyxo-hexopyranosyl)oxy)-2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7,12-tetr

Pharmacokinetics

11-hydroxyaclacinomycin X (ID-6105) is a novel anthracycline. We used an HPLC-based method which was validated in a pharmacokinetic study by suitable criteria.

ExcerptReference
"We investigated the pharmacokinetic characteristics of 11-hydroxyaclacinomycin X (ID-6105), a novel anthracycline, after intravenous (i."( HPLC analysis and pharmacokinetic characteristics of 11-hydroxyaclacinomycin X (ID-6105), a novel anthracycline, in rats and beagle dogs.
Ahan, KB; Chung, YB; Kang, MH; Kim, TY; Kwon, OS; Lee, HS; Moon, DC; Ryu, JS; Song, S; Yoo, BI, 2005)
" To analyze ID-6105 levels in biological samples, we used an HPLC-based method which was validated in a pharmacokinetic study by suitable criteria."( Pharmacokinetics of 11-hydroxyaclacinomycin X (ID-6105), a novel anthracycline, after i.v. bolus multiple administration in rats.
Ahan, KB; Chung, YB; Hong, YS; Kang, MH; Kim, TY; Kwon, OS; Lee, HS; Lee, JJ; Moon, DC; Ryu, JS; Song, S; Yoo, BI, 2005)

Dosage Studied

ExcerptReference
" We investigated ID6105-induced apoptosis and in vivo efficacy on experimental tumors, and also defined its optimal dosing schedule."( Apoptosis induced by ID6105, a new anthracycline (11-hydroxyaclacinomycin X, Hyrubicin), and its anti-tumor effects on experimental tumor models.
Hong, SK; Hong, YS; Jeon, YJ; Kim, TY; Lee, HS; Lee, JJ; Ryu, JS, 2007)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (28.57)18.2507
2000's5 (71.43)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
malondialdehyde
Malondialdehyde: The dialdehyde of malonic acid.. malonaldehyde : A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.		2.0310dialdehydebiomarker
aclacinomycin
aklavin: antibiotic prepared from culture liquids of streptomycete (A 1129); possessing antiphage activity; structure. aclacinomycin T : An anthracycline that is aklavinone having an alpha-L-rhodosaminyl residue attached at position 4 via a glycosidic linkage.		2.3920aminoglycoside;
anthracycline;
deoxy hexoside;
methyl ester;
monosaccharide derivative;
phenols;
polyketide;
tertiary alcohol;
tetracenequinones;
zwitterion		antimicrobial agent;
antineoplastic agent;
metabolite
aclarubicin
Aclarubicin: An anthracycline produced by Streptomyces galilaeus. It has potent antineoplastic activity.. aclacinomycin A : An anthracycline antibiotic that is produced by Streptomyces galilaeus and also has potent antineoplastic activity.		3.470aminoglycoside;
anthracycline;
methyl ester;
phenols;
polyketide;
tetracenequinones;
trisaccharide derivative;
zwitterion		antimicrobial agent;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Cancer of Ovary
[description not available]		02.0410
Ovarian Neoplasms
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.		02.0410
Experimental Neoplasms
[description not available]		02.0310
Leucocythaemia
[description not available]		01.9910
Malignant Melanoma
[description not available]		01.9910
Leukemia
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)		01.9910
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		01.9910